US Patent 7598417 Substituted fluoroethyl ureas as alpha 2 adrenergic agents
Patent 7598417 was granted and assigned to Allergan, Inc. on October, 2009 by the United States Patent and Trademark Office.
All edits
Edits on 17 Sep, 2023
Golden AI
Edits made to:
Infobox (+5 properties)
Infobox
Patent Inventor Names
Daniel W. Gil0
Evelyn G. Corpuz0
Ken Chow0
Michael E. Garst0
Wenkui K. Fang0
Edits on 16 Sep, 2023
Golden AI
Edits made to:
Article (+183 characters)
Article
Patent abstract
The present patent application is directed to novel fluoroethyl urea compounds and compositions and their therapeutic use in the treatment of pain and other conditions.
Edits on 15 Jul, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 07598417 Substituted fluoroethyl ureas as alpha 2 adrenergic agents US Patent 7598417 Substituted fluoroethyl ureas as alpha 2 adrenergic agents
Infobox
Patent Number
075984170
Patent Number
75984170
Edits on 21 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 7 Apr, 2023
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
075984170
Date of Patent
October 6, 2009
0Patent Application Number
120582190
Date Filed
March 28, 2008
0Official Website
Patent Primary Examiner
Edits on 18 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 3 Dec, 2021
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 07598417 Substituted fluoroethyl ureas as alpha 2 adrenergic agents
Infobox
Is a
Current assignee
Patent jurisdiction
Patent number
07598417
Date of patent
October 6, 2009
Patent application number
12058219
Date Filed
March 28, 2008
Patent primary examiner
Find more entities like US Patent 7598417 Substituted fluoroethyl ureas as alpha 2 adrenergic agents
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
